SCHEDULE 13D/A
SCHEDULE 13D/ASchedule 13D ownership disclosure
ITEOS THERAPEUTICS INC
Common Stock · CUSIP: 46565G104
Event date: 2025-05-13
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- MPM BioVentures 2014, L.P.Reported CIK 0001609492
Shares: 621,312.00 · Class: 1.6%
- MPM BioVentures 2014 (B), L.P.Reported CIK 0001609493
Shares: 39,135.00 · Class: 0.1%
- MPM Asset Management Investors BV2014 LLCReported CIK 0001609495
Shares: 21,385.00 · Class: 0.1%
- MPM BIOVENTURES 2018, L.P.Reported CIK 0001729505
Shares: 392,407.00 · Class: 1.0%
- MPM BIOVENTURES 2018 (B), L.P.Reported CIK 0001729504
Shares: 19,697.00 · Class: 0.1%
- MPM ASSET MANAGEMENT INVESTORS BV2018 LLCReported CIK 0001734817
Shares: 7,749.00 · Class: 0.0%
- UBS Oncology Impact Fund L.P.Reported CIK 0001691428
Shares: 702,311.00 · Class: 1.8%
- MPM BioVentures 2014 GP LLCReported CIK 0001765091
Shares: 660,447.00 · Class: 1.7%
- MPM BioVentures 2014 LLCReported CIK 0001765021
Shares: 681,832.00 · Class: 1.8%
- MPM BioVentures 2018 GP LLCReported CIK 0001818701
Shares: 412,104.00 · Class: 1.1%
- MPM BioVentures 2018 LLCReported CIK 0001818702
Shares: 419,853.00 · Class: 1.1%
- Oncology Impact Fund (Cayman) Management L.P.Reported CIK 0001721036
Shares: 702,311.00 · Class: 1.8%
- MPM BioImpact LLCReported CIK 0001687078
Shares: 702,311.00 · Class: 1.8%
- ANSBERT GADICKEReported CIK 0001134655
Shares: 1,803,996.00 · Class: 4.7%
- LUKE EVNINReported CIK 0001134657
Shares: 1,101,685.00 · Class: 2.9%
- Todd FoleyReported CIK 0001473930
Shares: 1,101,685.00 · Class: 2.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001415889-25-013244
- Form type
- SCHEDULE 13D/A
- Filer
- MPM BioVentures 2014, L.P.
- CIK
- CIK 1609492
- Filed
- May 15, 2025
- Reporting period
- May 13, 2025
- Description
- Schedule 13D beneficial ownership